
IQVIA Hlds (IQV) Stock Forecast & Price Target
IQVIA Hlds (IQV) Analyst Ratings
Bulls say
IQVIA Holdings is experiencing robust growth across its Financial Services Provider (FSP), Real World Evidence (RWE), and Contract Sales Management Services (CSMS) segments, indicating strong year-over-year performance in the third quarter. The company has demonstrated improving client decision timelines and a healthy pipeline, driven by recent drug launches, complemented by a significant increase in requests for proposals (RFPs) and an improved win rate in key segments. Additionally, IQVIA anticipates a continued positive trajectory with a projected growth rate of over 4% in its research and development services on a constant currency basis, bolstered by a favorable pricing environment.
Bears say
The financial analysis of IQVIA Holdings reveals a concerning trend in revenue growth, with a decline in year-over-year constant currency growth from 6.8% in 2Q25 to 3.8% in the most recent quarter. The company is facing difficult year-over-year comparisons and has expressed disappointment over potential growth falling below 5% in 2026, highlighting concerns about revenue stability moving forward. Additionally, operational challenges such as reduced hiring, pressures from passthroughs on margins, and the impact of rising interest rates on earnings further contribute to a negative outlook for the stock.
This aggregate rating is based on analysts' research of IQVIA Hlds and is not a guaranteed prediction by Public.com or investment advice.
IQVIA Hlds (IQV) Analyst Forecast & Price Prediction
Start investing in IQVIA Hlds (IQV)
Order type
Buy in
Order amount
Est. shares
0 shares